Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up
Background Hepatitis B vaccination in children born to hepatitis B surface antigen (HBsAg)-positive mothers considerably decreases the risk of vertical transmission. However, whether this protection against carriage of hepatitis B virus is maintained into early adulthood is as yet unknown. Patients...
Gespeichert in:
| Veröffentlicht in: | Infection 2010-10, Vol.38 (5), p.395-400 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 400 |
|---|---|
| container_issue | 5 |
| container_start_page | 395 |
| container_title | Infection |
| container_volume | 38 |
| creator | Roznovsky, L Orsagova, I Kloudova, A Tvrdik, J Kabieszova, L Lochman, I Mrazek, J Hozakova, L Zjevikova, A Pliskova, L |
| description | Background Hepatitis B vaccination in children born to hepatitis B surface antigen (HBsAg)-positive mothers considerably decreases the risk of vertical transmission. However, whether this protection against carriage of hepatitis B virus is maintained into early adulthood is as yet unknown. Patients and methods A combined passive-active immunization programme for newborns of HBsAg-positive mothers was initiated in the north-eastern part of the Czech Republic in 1988. The number of immunized newborns had reached 665 newborns by the end of 2006. All mothers of immunized infants were HBsAg-positive during pregnancy, and 34 (5%) were also hepatitis B e antigen (HBeAg)-positive. The immunization programme consists of providing newborns with protection at birth with hepatitis B immunoglobulin, followed by three 10-μg doses of plasma-derived or, since 1990, recombinant vaccine administered at 0, 1 and 6 months of life. Only 29 children of HBeAg-positive mothers received vaccine at 0, 1 and 2 months of life. Blood samples were obtained after immunization, at 2 years of age, and biennially thereafter. Samples were tested for HBsAg and hepatitis B surface and core antibodies (anti-HBs, anti-HBc). Results The immunization schedules were completed in 640 children. A protective anti-HBs level after immunization was proven in 574 of 620 children (93%). Persistence of protective anti-HBs antibodies was detected in 70, 40 and 25% of children at 5, 10 and 15 years of age. Vertical transmission with chronic HBsAg carrier status was detected in two infants. Anti-HBc seroconversion was proven in ten children from 3 to 15 years of age. Natural boosting with an anti-HBs increase was detected in 38 children (twice in one child). Conclusion Our results show that combined active-passive immunization of newborns against hepatitis B provides persistent protection up to adolescence despite a frequent waning of anti-HBs antibodies, suggesting there is no need for booster vaccination during adolescence. |
| doi_str_mv | 10.1007/s15010-010-0039-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_815537847</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>755399675</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-bbb8294815c52d681e81692a5a7af59dc0ef7b0b4d52a07b8463eda92e17eed13</originalsourceid><addsrcrecordid>eNqF0c-P1CAUB3BiNO64-gd40cbEeEIfUArsTTf-SibxoHMmr5SO3XRghNbN_vfS7egmHvRAIOHDe498CXnK4DUDUG8yk8CA3i4Qhqp7ZMPqcgCjxH2yAQFANePNGXmU8xUASFOrh-SMg9RGcr4hu20Mezr5dKiOKU7eTUMMFe5xCHmqvvsjTsM05OpdhX1RVfDXbUyh-onODQEXfVFxoDceU9XHcYzXdD4-Jg96HLN_ctrPye7D-2-Xn-j2y8fPl2-31NWymWjbtpqbWjPpJO8azbxmjeEoUWEvTefA96qFtu4kR1CtrhvhOzTcM-V9x8Q5ebXWLbP_mH2e7GHIzo8jBh_nbEtlKZSu1X-lKtCYRskiX_wlr-KcQvlGQQ2rG8mhILYil2LOyff2mIYDphvLwC7Z2DUbe7tKNnYZ4dmp8NwefPfnxe8wCnh5Apgdjn3C4IZ854Qu-YnF8dXlchX2Pt1N-K_uz9dHPUaL-1QK775yYALY0l0p8QsFv65X</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>756146520</pqid></control><display><type>article</type><title>Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Roznovsky, L ; Orsagova, I ; Kloudova, A ; Tvrdik, J ; Kabieszova, L ; Lochman, I ; Mrazek, J ; Hozakova, L ; Zjevikova, A ; Pliskova, L</creator><creatorcontrib>Roznovsky, L ; Orsagova, I ; Kloudova, A ; Tvrdik, J ; Kabieszova, L ; Lochman, I ; Mrazek, J ; Hozakova, L ; Zjevikova, A ; Pliskova, L</creatorcontrib><description>Background Hepatitis B vaccination in children born to hepatitis B surface antigen (HBsAg)-positive mothers considerably decreases the risk of vertical transmission. However, whether this protection against carriage of hepatitis B virus is maintained into early adulthood is as yet unknown. Patients and methods A combined passive-active immunization programme for newborns of HBsAg-positive mothers was initiated in the north-eastern part of the Czech Republic in 1988. The number of immunized newborns had reached 665 newborns by the end of 2006. All mothers of immunized infants were HBsAg-positive during pregnancy, and 34 (5%) were also hepatitis B e antigen (HBeAg)-positive. The immunization programme consists of providing newborns with protection at birth with hepatitis B immunoglobulin, followed by three 10-μg doses of plasma-derived or, since 1990, recombinant vaccine administered at 0, 1 and 6 months of life. Only 29 children of HBeAg-positive mothers received vaccine at 0, 1 and 2 months of life. Blood samples were obtained after immunization, at 2 years of age, and biennially thereafter. Samples were tested for HBsAg and hepatitis B surface and core antibodies (anti-HBs, anti-HBc). Results The immunization schedules were completed in 640 children. A protective anti-HBs level after immunization was proven in 574 of 620 children (93%). Persistence of protective anti-HBs antibodies was detected in 70, 40 and 25% of children at 5, 10 and 15 years of age. Vertical transmission with chronic HBsAg carrier status was detected in two infants. Anti-HBc seroconversion was proven in ten children from 3 to 15 years of age. Natural boosting with an anti-HBs increase was detected in 38 children (twice in one child). Conclusion Our results show that combined active-passive immunization of newborns against hepatitis B provides persistent protection up to adolescence despite a frequent waning of anti-HBs antibodies, suggesting there is no need for booster vaccination during adolescence.</description><identifier>ISSN: 0300-8126</identifier><identifier>EISSN: 1439-0973</identifier><identifier>DOI: 10.1007/s15010-010-0039-7</identifier><identifier>PMID: 20589522</identifier><identifier>CODEN: IFTNAL</identifier><language>eng</language><publisher>Munchen: Munchen : Urban and Vogel</publisher><subject>Adolescent ; Adolescents ; Antibody waning ; Biological and medical sciences ; Brief Report ; Child ; Child, Preschool ; Children ; Family Medicine ; Female ; Follow-Up Studies ; General Practice ; Hepatitis ; Hepatitis Antigens - blood ; Hepatitis Antigens - immunology ; Hepatitis B - immunology ; Hepatitis B - prevention & control ; Hepatitis B - virology ; Hepatitis B Antibodies - blood ; Hepatitis B Antibodies - immunology ; Hepatitis B Vaccines - administration & dosage ; Hepatitis B Vaccines - immunology ; Hepatitis B virus ; Hepatitis B virus - immunology ; Humans ; Immunization ; Immunization Schedule ; Infant ; Infant, Newborn ; Infants ; Infectious Disease Transmission, Vertical - prevention & control ; Infectious Diseases ; Internal Medicine ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Miscellaneous ; Newborn ; Pregnancy ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Risk reduction ; Time ; Transmission ; Vaccination ; Vaccine ; Vaccines ; viral hepatitis</subject><ispartof>Infection, 2010-10, Vol.38 (5), p.395-400</ispartof><rights>Urban & Vogel 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-bbb8294815c52d681e81692a5a7af59dc0ef7b0b4d52a07b8463eda92e17eed13</citedby><cites>FETCH-LOGICAL-c456t-bbb8294815c52d681e81692a5a7af59dc0ef7b0b4d52a07b8463eda92e17eed13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s15010-010-0039-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s15010-010-0039-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23805932$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20589522$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roznovsky, L</creatorcontrib><creatorcontrib>Orsagova, I</creatorcontrib><creatorcontrib>Kloudova, A</creatorcontrib><creatorcontrib>Tvrdik, J</creatorcontrib><creatorcontrib>Kabieszova, L</creatorcontrib><creatorcontrib>Lochman, I</creatorcontrib><creatorcontrib>Mrazek, J</creatorcontrib><creatorcontrib>Hozakova, L</creatorcontrib><creatorcontrib>Zjevikova, A</creatorcontrib><creatorcontrib>Pliskova, L</creatorcontrib><title>Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up</title><title>Infection</title><addtitle>Infection</addtitle><addtitle>Infection</addtitle><description>Background Hepatitis B vaccination in children born to hepatitis B surface antigen (HBsAg)-positive mothers considerably decreases the risk of vertical transmission. However, whether this protection against carriage of hepatitis B virus is maintained into early adulthood is as yet unknown. Patients and methods A combined passive-active immunization programme for newborns of HBsAg-positive mothers was initiated in the north-eastern part of the Czech Republic in 1988. The number of immunized newborns had reached 665 newborns by the end of 2006. All mothers of immunized infants were HBsAg-positive during pregnancy, and 34 (5%) were also hepatitis B e antigen (HBeAg)-positive. The immunization programme consists of providing newborns with protection at birth with hepatitis B immunoglobulin, followed by three 10-μg doses of plasma-derived or, since 1990, recombinant vaccine administered at 0, 1 and 6 months of life. Only 29 children of HBeAg-positive mothers received vaccine at 0, 1 and 2 months of life. Blood samples were obtained after immunization, at 2 years of age, and biennially thereafter. Samples were tested for HBsAg and hepatitis B surface and core antibodies (anti-HBs, anti-HBc). Results The immunization schedules were completed in 640 children. A protective anti-HBs level after immunization was proven in 574 of 620 children (93%). Persistence of protective anti-HBs antibodies was detected in 70, 40 and 25% of children at 5, 10 and 15 years of age. Vertical transmission with chronic HBsAg carrier status was detected in two infants. Anti-HBc seroconversion was proven in ten children from 3 to 15 years of age. Natural boosting with an anti-HBs increase was detected in 38 children (twice in one child). Conclusion Our results show that combined active-passive immunization of newborns against hepatitis B provides persistent protection up to adolescence despite a frequent waning of anti-HBs antibodies, suggesting there is no need for booster vaccination during adolescence.</description><subject>Adolescent</subject><subject>Adolescents</subject><subject>Antibody waning</subject><subject>Biological and medical sciences</subject><subject>Brief Report</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Family Medicine</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>General Practice</subject><subject>Hepatitis</subject><subject>Hepatitis Antigens - blood</subject><subject>Hepatitis Antigens - immunology</subject><subject>Hepatitis B - immunology</subject><subject>Hepatitis B - prevention & control</subject><subject>Hepatitis B - virology</subject><subject>Hepatitis B Antibodies - blood</subject><subject>Hepatitis B Antibodies - immunology</subject><subject>Hepatitis B Vaccines - administration & dosage</subject><subject>Hepatitis B Vaccines - immunology</subject><subject>Hepatitis B virus</subject><subject>Hepatitis B virus - immunology</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization Schedule</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Infants</subject><subject>Infectious Disease Transmission, Vertical - prevention & control</subject><subject>Infectious Diseases</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Miscellaneous</subject><subject>Newborn</subject><subject>Pregnancy</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Risk reduction</subject><subject>Time</subject><subject>Transmission</subject><subject>Vaccination</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>viral hepatitis</subject><issn>0300-8126</issn><issn>1439-0973</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqF0c-P1CAUB3BiNO64-gd40cbEeEIfUArsTTf-SibxoHMmr5SO3XRghNbN_vfS7egmHvRAIOHDe498CXnK4DUDUG8yk8CA3i4Qhqp7ZMPqcgCjxH2yAQFANePNGXmU8xUASFOrh-SMg9RGcr4hu20Mezr5dKiOKU7eTUMMFe5xCHmqvvsjTsM05OpdhX1RVfDXbUyh-onODQEXfVFxoDceU9XHcYzXdD4-Jg96HLN_ctrPye7D-2-Xn-j2y8fPl2-31NWymWjbtpqbWjPpJO8azbxmjeEoUWEvTefA96qFtu4kR1CtrhvhOzTcM-V9x8Q5ebXWLbP_mH2e7GHIzo8jBh_nbEtlKZSu1X-lKtCYRskiX_wlr-KcQvlGQQ2rG8mhILYil2LOyff2mIYDphvLwC7Z2DUbe7tKNnYZ4dmp8NwefPfnxe8wCnh5Apgdjn3C4IZ854Qu-YnF8dXlchX2Pt1N-K_uz9dHPUaL-1QK775yYALY0l0p8QsFv65X</recordid><startdate>20101001</startdate><enddate>20101001</enddate><creator>Roznovsky, L</creator><creator>Orsagova, I</creator><creator>Kloudova, A</creator><creator>Tvrdik, J</creator><creator>Kabieszova, L</creator><creator>Lochman, I</creator><creator>Mrazek, J</creator><creator>Hozakova, L</creator><creator>Zjevikova, A</creator><creator>Pliskova, L</creator><general>Munchen : Urban and Vogel</general><general>Urban and Vogel</general><general>Springer</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20101001</creationdate><title>Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up</title><author>Roznovsky, L ; Orsagova, I ; Kloudova, A ; Tvrdik, J ; Kabieszova, L ; Lochman, I ; Mrazek, J ; Hozakova, L ; Zjevikova, A ; Pliskova, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-bbb8294815c52d681e81692a5a7af59dc0ef7b0b4d52a07b8463eda92e17eed13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adolescent</topic><topic>Adolescents</topic><topic>Antibody waning</topic><topic>Biological and medical sciences</topic><topic>Brief Report</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Family Medicine</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>General Practice</topic><topic>Hepatitis</topic><topic>Hepatitis Antigens - blood</topic><topic>Hepatitis Antigens - immunology</topic><topic>Hepatitis B - immunology</topic><topic>Hepatitis B - prevention & control</topic><topic>Hepatitis B - virology</topic><topic>Hepatitis B Antibodies - blood</topic><topic>Hepatitis B Antibodies - immunology</topic><topic>Hepatitis B Vaccines - administration & dosage</topic><topic>Hepatitis B Vaccines - immunology</topic><topic>Hepatitis B virus</topic><topic>Hepatitis B virus - immunology</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization Schedule</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Infants</topic><topic>Infectious Disease Transmission, Vertical - prevention & control</topic><topic>Infectious Diseases</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Miscellaneous</topic><topic>Newborn</topic><topic>Pregnancy</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Risk reduction</topic><topic>Time</topic><topic>Transmission</topic><topic>Vaccination</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>viral hepatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roznovsky, L</creatorcontrib><creatorcontrib>Orsagova, I</creatorcontrib><creatorcontrib>Kloudova, A</creatorcontrib><creatorcontrib>Tvrdik, J</creatorcontrib><creatorcontrib>Kabieszova, L</creatorcontrib><creatorcontrib>Lochman, I</creatorcontrib><creatorcontrib>Mrazek, J</creatorcontrib><creatorcontrib>Hozakova, L</creatorcontrib><creatorcontrib>Zjevikova, A</creatorcontrib><creatorcontrib>Pliskova, L</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roznovsky, L</au><au>Orsagova, I</au><au>Kloudova, A</au><au>Tvrdik, J</au><au>Kabieszova, L</au><au>Lochman, I</au><au>Mrazek, J</au><au>Hozakova, L</au><au>Zjevikova, A</au><au>Pliskova, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up</atitle><jtitle>Infection</jtitle><stitle>Infection</stitle><addtitle>Infection</addtitle><date>2010-10-01</date><risdate>2010</risdate><volume>38</volume><issue>5</issue><spage>395</spage><epage>400</epage><pages>395-400</pages><issn>0300-8126</issn><eissn>1439-0973</eissn><coden>IFTNAL</coden><abstract>Background Hepatitis B vaccination in children born to hepatitis B surface antigen (HBsAg)-positive mothers considerably decreases the risk of vertical transmission. However, whether this protection against carriage of hepatitis B virus is maintained into early adulthood is as yet unknown. Patients and methods A combined passive-active immunization programme for newborns of HBsAg-positive mothers was initiated in the north-eastern part of the Czech Republic in 1988. The number of immunized newborns had reached 665 newborns by the end of 2006. All mothers of immunized infants were HBsAg-positive during pregnancy, and 34 (5%) were also hepatitis B e antigen (HBeAg)-positive. The immunization programme consists of providing newborns with protection at birth with hepatitis B immunoglobulin, followed by three 10-μg doses of plasma-derived or, since 1990, recombinant vaccine administered at 0, 1 and 6 months of life. Only 29 children of HBeAg-positive mothers received vaccine at 0, 1 and 2 months of life. Blood samples were obtained after immunization, at 2 years of age, and biennially thereafter. Samples were tested for HBsAg and hepatitis B surface and core antibodies (anti-HBs, anti-HBc). Results The immunization schedules were completed in 640 children. A protective anti-HBs level after immunization was proven in 574 of 620 children (93%). Persistence of protective anti-HBs antibodies was detected in 70, 40 and 25% of children at 5, 10 and 15 years of age. Vertical transmission with chronic HBsAg carrier status was detected in two infants. Anti-HBc seroconversion was proven in ten children from 3 to 15 years of age. Natural boosting with an anti-HBs increase was detected in 38 children (twice in one child). Conclusion Our results show that combined active-passive immunization of newborns against hepatitis B provides persistent protection up to adolescence despite a frequent waning of anti-HBs antibodies, suggesting there is no need for booster vaccination during adolescence.</abstract><cop>Munchen</cop><pub>Munchen : Urban and Vogel</pub><pmid>20589522</pmid><doi>10.1007/s15010-010-0039-7</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-8126 |
| ispartof | Infection, 2010-10, Vol.38 (5), p.395-400 |
| issn | 0300-8126 1439-0973 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_815537847 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adolescent Adolescents Antibody waning Biological and medical sciences Brief Report Child Child, Preschool Children Family Medicine Female Follow-Up Studies General Practice Hepatitis Hepatitis Antigens - blood Hepatitis Antigens - immunology Hepatitis B - immunology Hepatitis B - prevention & control Hepatitis B - virology Hepatitis B Antibodies - blood Hepatitis B Antibodies - immunology Hepatitis B Vaccines - administration & dosage Hepatitis B Vaccines - immunology Hepatitis B virus Hepatitis B virus - immunology Humans Immunization Immunization Schedule Infant Infant, Newborn Infants Infectious Disease Transmission, Vertical - prevention & control Infectious Diseases Internal Medicine Male Medical sciences Medicine Medicine & Public Health Miscellaneous Newborn Pregnancy Public health. Hygiene Public health. Hygiene-occupational medicine Risk reduction Time Transmission Vaccination Vaccine Vaccines viral hepatitis |
| title | Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T20%3A05%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20protection%20against%20hepatitis%20B%20after%20newborn%20vaccination:%2020-year%20follow-up&rft.jtitle=Infection&rft.au=Roznovsky,%20L&rft.date=2010-10-01&rft.volume=38&rft.issue=5&rft.spage=395&rft.epage=400&rft.pages=395-400&rft.issn=0300-8126&rft.eissn=1439-0973&rft.coden=IFTNAL&rft_id=info:doi/10.1007/s15010-010-0039-7&rft_dat=%3Cproquest_cross%3E755399675%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=756146520&rft_id=info:pmid/20589522&rfr_iscdi=true |